REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in upcoming virtual investor conferences. Key events include a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, and another at Chardan's 5th Annual Genetic Medicines Conference on October 5, 2021. Webcasts for these chats will be available on the company's website for 90 days post-event. REGENXBIO specializes in gene therapy utilizing its proprietary NAV Technology Platform, which includes over 100 AAV vectors aimed at various therapeutic applications.
- None.
- None.
ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:
Morgan Stanley 19th Annual Global Healthcare Conference
Fireside Chat: Tuesday, September 14, 2021 at 3:30 p.m. E.T.
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines
Date: Wednesday, September 22, 2021
Chardan's 5th Annual Genetic Medicines Conference
Fireside Chat: Wednesday, October 5, 2021 at 4:00 p.m. E.T.
Live webcasts of the Morgan Stanley and Chardan fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcasts will be available on the same website for approximately 90 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301370587.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO's participation in the Morgan Stanley Conference?
What is the date of REGENXBIO's presentation at the SVB Leerink Conference?
When will the webcast for the Chardan Conference be available?
What technology does REGENXBIO utilize for gene therapy?
Where can I access REGENXBIO's investor presentations?
